• Publications
  • Influence
The Effects of Surgical Cytoreduction Prior to Imatinib Therapy on the Prognosis of Patients with Advanced GIST
BackgroundBaseline tumor size is one of important prognostic factors for imatinib therapy in patients with advanced gastrointestinal stromal tumor (GIST). The purpose of this study was to determineExpand
  • 30
  • 3
Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP
Positron emission tomography (PET) has been found useful in monitoring response to treatment of malignant lymphoma. We investigated the ability of interim PET to monitor response to standard doseExpand
  • 70
  • 2
The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients
Objective: This study evaluated the clinical relevance of KRAS and BRAF mutational status in 66 irinotecan-refrac- tory Korean metastatic colorectal cancer (mCRC) patients treated withExpand
  • 26
  • 2
Epithelial-myoepithelial carcinoma of the nasopharynx: A case report and review of the literature.
An 80-year-old female with complaints of right-sided nose blockage and occasional epistaxis for several months was referred to Sanggye Paik Hospital (Seoul, Korea). Nasal examination revealed aExpand
  • 5
  • 2
  • PDF
The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
BackgroundAlthough benefits of surgical resection of residual gastrointestinal stromal tumors (GISTs) after imatinib therapy have been suggested, those benefits over imatinib alone have not beenExpand
  • 33
  • 1
Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor
In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs).Expand
  • 27
  • 1
Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of
OBJECTIVE Following our previous report on acute exacerbation of chronic hepatitis B in breast cancer patients receiving anthracyline-based adjuvant chemotherapy, updated longitudinal data wereExpand
  • 12
  • 1
A Case of Histiocytic Sarcoma Presenting with Primary Bone Marrow Involvement
Histiocytic sarcoma (HS) is a very rare neoplasm that often shows an aggressive clinical course and systemic symptoms, such as fever, weight loss, adenopathy, hepatosplenomegaly and pancytopenia. ItExpand
  • 12
  • 1
  • PDF
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
  • S. Kim, J. Kang, +13 authors H. Lim
  • Medicine
  • Annals of oncology : official journal of the…
  • 1 May 2019
BACKGROUND Capecitabine plus oxaliplatin (XELOX) has shown modest activity and tolerable toxicity in a phase II trial for biliary tract cancers (BTCs). Meanwhile, gemcitabine plus oxaliplatin (GEMOX)Expand
  • 10
  • 1
Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma
Although patients with T-cell phenotype lymphomas are generally accepted to have worse prognosis than B-cell phenotype lymphomas, the studies comparing outcomes after autologous stem cellExpand
  • 7
  • 1